It would therefore be more advantageous to combine the hypoxia targets with targets from other oncogenic pathways, such as growth factors (e.g. EGFR or HER2), targets that are excreted in the tumor stroma (e.g. Vascular Endothelial Growth Factor (VEGF)), or less tumor-specific targets such as Mucin 1 (MUC1), Mammaglobin, or CD44v6 [36]. Here, EGFR is linked to neoplasm.